{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T09:57:07Z","timestamp":1781863027231,"version":"3.54.5"},"reference-count":31,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Extramedullary disease (EMD) is an aggressive and treatment-resistant manifestation of multiple myeloma with limited therapeutic options, particularly in heavily pretreated patients. Methods: We conducted a retrospective study to evaluate the efficacy and safety of concurrent immune checkpoint inhibitors (ICIs) and radiation therapy (RT) in patients with EMD treated at Hackensack University Medical Center and John Theurer Cancer Center between January 2016 and May 2025. Patients were included if they had confirmed EMD and received nivolumab or pembrolizumab with concurrent RT. Results: A total of 21 patients were included, representing a high-risk cohort with a median of 6 prior lines of therapy (range 2\u201313), including 47.6% triple-class refractory and 19.0% penta-refractory disease. The overall response rate (ORR) was 47.6%, with a clinical benefit rate of 57.1%. Despite these responses, median progression-free survival (PFS) and overall survival (OS) were 4 and 12 months, respectively. Notably, two patients achieved complete responses with nivolumab and RT early in their treatment course following cellular therapy and remain disease-free at last follow-up. The combination of ICIs and RT was generally well-tolerated, with manageable immune-related adverse events and no treatment-related deaths. Conclusions: These findings suggest that concurrent ICI and RT may provide a signal of treatment responses in a subset of patients with advanced EMD, although durability remains limited. Further prospective studies are warranted to further define the role of this combination and identify patients most likely to benefit.<\/jats:p>","DOI":"10.3390\/cancers18121996","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T09:18:43Z","timestamp":1781860723000},"page":"1996","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined Immune Checkpoint Inhibitors and Radiation Therapy in Patients with Multiple Myeloma and Extramedullary Medullary Disease: A Real-World Retrospective Analysis"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4771-4970","authenticated-orcid":false,"given":"Lili","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, John Theurer Cancer Center, Hackensack, NJ 07601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2133-2480","authenticated-orcid":false,"given":"Ayrton","family":"Bangolo","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, John Theurer Cancer Center, Hackensack, NJ 07601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Amoozgar","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, John Theurer Cancer Center, Hackensack, NJ 07601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarvarinder","family":"Gill","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, John Theurer Cancer Center, Hackensack, NJ 07601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahe","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, John Theurer Cancer Center, Hackensack, NJ 07601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurpavitar Singh","family":"Bhullar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindhu","family":"Singareddy","sequence":"additional","affiliation":[{"name":"Department of Medicine, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubhangi","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Muench","sequence":"additional","affiliation":[{"name":"Department of Medicine, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Peake","sequence":"additional","affiliation":[{"name":"Department of Medicine, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komal","family":"Azam","sequence":"additional","affiliation":[{"name":"Department of Medicine, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie","family":"Noe","sequence":"additional","affiliation":[{"name":"Department of Medicine, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jericho","family":"Ghanem","sequence":"additional","affiliation":[{"name":"Department of Medicine, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eme","family":"De Graaf","sequence":"additional","affiliation":[{"name":"Department of Medicine, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashrika","family":"Sookoo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjunath N. R. K.","family":"Reddy","sequence":"additional","affiliation":[{"name":"Department of Medicine, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selbin","family":"Boban","sequence":"additional","affiliation":[{"name":"Department of Medicine, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikder","family":"Sakil","sequence":"additional","affiliation":[{"name":"Department of Medicine, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duval","family":"Samwaru","sequence":"additional","affiliation":[{"name":"Department of Medicine, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keerthi","family":"Sadasivan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Baracewicz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Manoja","family":"Bheemineni","sequence":"additional","affiliation":[{"name":"Department of Medicine, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahejdeep","family":"Chohan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simcha","family":"Weissman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh","family":"Parmar","sequence":"additional","affiliation":[{"name":"Division of Myeloma, John Theurer Cancer Center, Hackensack, NJ 07601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Phull","sequence":"additional","affiliation":[{"name":"Division of Myeloma, John Theurer Cancer Center, Hackensack, NJ 07601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Siegel","sequence":"additional","affiliation":[{"name":"Division of Myeloma, John Theurer Cancer Center, Hackensack, NJ 07601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Vesole","sequence":"additional","affiliation":[{"name":"Division of Myeloma, John Theurer Cancer Center, Hackensack, NJ 07601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Biran","sequence":"additional","affiliation":[{"name":"Division of Myeloma, John Theurer Cancer Center, Hackensack, NJ 07601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.17849\/insm-47-04-1-9.1","article-title":"Plasma Cell Myeloma\u201420-Year Comparative Survival and Mortality of Three Plasma Cell Myeloma ICD-O-3 Oncologic Phenotypes by Age, Sex, Race, Stage, Cohort Entry Time-Period and Disease Duration: A Systematic Review of 111,041 Cases for Diagnosis Years 1973\u20132014: (SEER*Stat 8.3.4)","volume":"47","author":"Milano","year":"2018","journal-title":"J. Insur. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.5306\/wjco.v14.i4.179","article-title":"Interaction between Age and Gender on Survival Outcomes in Extramedullary Multiple Myeloma over the Past Two Decades","volume":"14","author":"Bangolo","year":"2023","journal-title":"World J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","article-title":"Multiple Myeloma with High-Risk Cytogenetics and Its Treatment Approach","volume":"115","author":"Hanamura","year":"2022","journal-title":"Int. J. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s11899-021-00631-7","article-title":"Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma","volume":"16","author":"Marneni","year":"2021","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","article-title":"Extramedullary Disease Portends Poor Prognosis in Multiple Myeloma and Is Over-Represented in High-Risk Disease Even in the Era of Novel Agents","volume":"97","author":"Usmani","year":"2012","journal-title":"Haematologica"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/ajh.27023","article-title":"Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma","volume":"98","author":"Zanwar","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1470-2045(25)00653-9","article-title":"Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4): An Updated Analysis Including Overall Survival from an Open-Label, Multicentre, Randomised, Phase 3 Trial","volume":"27","author":"Einsele","year":"2026","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Li, Y.-L., Li, M.-J., Li, J.-J., Chen, D., Li, C.-Y., Qiu, L., He, Y., Fan, J.-C., Ren, S.-H., and Yao, H. (2026). Efficacy and Safety of BCMA-Directed CAR T-Cell Therapy in Extramedullary Relapsed or Refractory Multiple Myeloma: A Meta-Analysis. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1792558"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell\u2013Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41408-025-01330-9","article-title":"Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement","volume":"15","author":"Steinhardt","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e693","DOI":"10.1016\/S2352-3026(24)00186-8","article-title":"Mechanisms of Resistance against T-Cell Engaging Bispecific Antibodies in Multiple Myeloma: Implications for Novel Treatment Strategies","volume":"11","author":"Chari","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMoa2514752","article-title":"Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab","volume":"394","author":"Kumar","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Abuhelwa, Z., Amisha, F., Fan, W., De Avila, G., Hansen, D.K., Grajales-Cruz, A.F., Blue, B., Castaneda, O., Liu, H., and Freeman, C.L. (2025). Post-Progression Outcomes Following BCMA-Directed CAR T-Cell Therapy in Myeloma: Impact of Extramedullary and Paramedullary Disease. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1663814"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s41573-023-00807-1","article-title":"Mechanisms of Resistance to Chimeric Antigen Receptor-T Cells in Haematological Malignancies","volume":"22","author":"Ruella","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s12032-025-02753-x","article-title":"BCMA-Targeted Therapies in Multiple Myeloma: Advances, Challenges and Future Prospects","volume":"42","author":"Amin","year":"2025","journal-title":"Med. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus Pomalidomide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma (KEYNOTE-183): A Randomised, Open-Label, Phase 3 Trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Guerini, A.E., Tucci, A., Alongi, F., Mataj, E., Belotti, A., Borghetti, P., Triggiani, L., Pegurri, L., Pedretti, S., and Bon\u00f9, M. (2022). RR Myelo POINT: A Retrospective Single-Center Study Assessing the Role of Radiotherapy in the Management of Multiple Myeloma and Possible Interactions with Concurrent Systemic Treatment. Cancers, 14.","DOI":"10.3390\/cancers14092273"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/ejh.70145","article-title":"Extramedullary Multiple Myeloma","volume":"116","author":"Jingliang","year":"2026","journal-title":"Eur. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Franzin, R., Netti, G.S., Spadaccino, F., Porta, C., Gesualdo, L., Stallone, G., Castellano, G., and Ranieri, E. (2020). The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.574271"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Alkharabsheh, O., Trisel, Z., Badami, S., Aljama, M.A., and Sidiqi, M.H. (2021). Checkpoint Inhibitors in Multiple Myeloma: Intriguing Potential and Unfulfilled Promises. Cancers, 14.","DOI":"10.3390\/cancers14010113"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/phar.1871","article-title":"Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy","volume":"37","author":"Chung","year":"2017","journal-title":"Pharmacotherapy"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"101696","DOI":"10.1016\/j.adro.2024.101696","article-title":"Impact of the Number of Administered Systemic Treatment Lines on Local Response to Radiation Therapy for Multiple Myeloma","volume":"10","author":"Guerini","year":"2025","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/17474086.2024.2357274","article-title":"Anti-BCMA CAR-T Cell-Based Therapies and Bispecific Antibodies in the Immunotherapy Era: Are We Ready for This?","volume":"17","author":"Martino","year":"2024","journal-title":"Expert Rev. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13045-025-01713-2","article-title":"BCMA\/GPRC5D Bispecific CAR T-Cell Therapy for Relapsed\/Refractory Multiple Myeloma with Extramedullary Disease: A Single-Center, Single-Arm, Phase 1 Trial","volume":"18","author":"Yao","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.clml.2023.12.001","article-title":"Characterization and Outcomes of Spanish Patients With Relapsed\/Refractory Multiple Myeloma Included in the LocoMMotion Study","volume":"24","author":"Mateos","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.clml.2025.03.014","article-title":"Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed\/Refractory Multiple Myeloma from the Pooled LocoMMotion and MoMMent Studies","volume":"25","author":"Moreau","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12325-025-03409-y","article-title":"Comparative Efficacy of Talquetamab vs. Real-World Physician\u2019s Choice of Treatment in Triple-Class-Exposed Relapsed\/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion\/MoMMent","volume":"43","author":"Einsele","year":"2026","journal-title":"Adv. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/ajco.13783","article-title":"Large Variation in Radiation Therapy Fractionation for Multiple Myeloma in Australia","volume":"19","author":"Ong","year":"2023","journal-title":"Asia-Pac. J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s12185-021-03139-1","article-title":"Pembrolizumab plus Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma (KEYNOTE-183): Subgroup Analysis in Japanese Patients","volume":"113","author":"Matsumoto","year":"2021","journal-title":"Int. J. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1001\/jamaoncol.2021.6439","article-title":"Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy: A Pooled Analysis of Trials in the US Food and Drug Administration Database","volume":"8","author":"Anscher","year":"2022","journal-title":"JAMA Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/12\/1996\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T09:31:56Z","timestamp":1781861516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/12\/1996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":31,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["cancers18121996"],"URL":"https:\/\/doi.org\/10.3390\/cancers18121996","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]}}}